XML 24 R8.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Cash Flows
 12 Months Ended
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Cash flows from operating activities:      
Net loss $ (73,740,339) $ (29,102,837) $ (36,140,133)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 1,708,498 1,048,431 626,554
Amortization of intangible assets 1,377,466 870,199 942,719
Change in value of common stock warrants (127,554) (177,561) (348,143)
Stock-based compensation 10,479,135 6,186,848 5,428,946
Issuance of shares in connection with reverse stock split 0 0 57,187
Amortization of premiums on investments 266,290 348,566 54,534
Deferred taxes (849) 14,166 27,537
Deferred rent (16,728) 383,584 762,616
Loss on short-term investments 139,249 432,174 36,949
Gain on investment in affiliated entity (1,110,787) (2,600,467) (2,676,224)
Gain on sale of intangible assets (1,000,000) (1,000,000) 0
Income tax benefit from other unrealized gains on securities 0 (2,097,766) 0
Changes in operating assets and liabilities:      
Accounts receivable (8,521,899) (4,497,225) 499,176
Accounts receivable from affiliated entity (714,908) (31,627) (1,820)
Prepaid expenses and other current assets (831,802) (119,284) (160,540)
Prepaid expenses and other current assets from affiliated entity (901,772) 771,723 674,975
Restricted cash 0 0 100,762
Other assets (1,442,314) (196,265) (72,493)
Accounts payable and accrued expenses 6,367,965 6,456,581 925,820
Accrued clinical trial expenses 3,767,906 593,051 561,252
Accounts payable and accrued expenses due to affiliated entity 907,532 136,640 (493,848)
Deferred revenue 1,527,686 10,191,840 (260,719)
Deferred revenue from affiliated entity (687,827) (49,672) (368,751)
Net cash used in operating activities (62,555,052) (12,438,901) (29,823,644)
Cash flows from investing activities:      
Purchases of investments (57,317,671) (63,526,830) (47,185,945)
Maturities of investments 76,528,030 10,484,267 12,753,719
Purchases of capital assets (2,738,470) (2,781,544) (1,379,980)
Proceeds from sale of intangible assets 1,000,000 1,000,000 0
Purchase of intangible and other assets (1,200,000) 0 0
Net cash provided by (used in) investing activities 16,271,889 (54,824,107) (35,812,206)
Cash flows from financing activities:      
Proceeds from issuance of common stock and warrants, net of issuance costs 6,295,761 81,902,363 59,209,182
Proceeds from stock option and warrant exercises, net of tax payments 1,640,740 2,598,915 13,252,543
Other financing activities (149,559) (149,559) 0
Net cash provided by financing activities 7,786,942 84,351,719 72,461,725
Effect of exchange rate changes on cash and cash equivalents 0 0 (1,689)
Increase (Decrease) in cash and cash equivalents (38,496,221) 17,088,711 6,824,186
Cash and cash equivalents, beginning of period 57,632,693 40,543,982 33,719,796
Cash and cash equivalents, end of period 19,136,472 57,632,693 40,543,982
Supplemental disclosure of non-cash activities      
Common stock issued for purchase of Bioject 4,300,000 0 0
Change in amounts accrued for purchases of property and equipment 164,923 225,148 12,842
Lease incentive recorded as fixed assets and deferred rent $ 523,856 $ 773,000 $ 933,000